Author Page for Nan Ding

Overall Survival of Patients with De Novo HER2-Positive Metastatic Breast Cancer in the Netherlands from 2008 to 2017: A Population-Based Cohort Study

Number of pages: 29 Posted: 06 Feb 2025

Nan Ding, Karlijn E.P.E. Hermans, Thiemo J.A. van Nijnatten, Sanne M.E. Engelen, Jolien Tol, Loes Kooreman, Marie-Jeanne T.F.D. Vrancken Peeters, Sabine Siesling, Adri C. Voogd, Vivianne C.G. Tjan-Heijnen and Sandra M.E. Geurts

Maastricht University, Maastricht University, Maastricht University - Department of Radiology and Nuclear Medicine, Maastricht University - Department of Surgery, Jeroen Bosch Hospital, Maastricht University, Netherlands Cancer Institute Antoni van Leeuwenhoek, Netherlands Comprehensive Cancer Organisation, Maastricht University, Maastricht University and Maastricht University

Downloads 106

Abstract:

Overall Survival of Patients with de novo HER2-Positive Metastatic Breast Cancer in the Netherlands from 2008 to 2017: A Population-Based Cohort Study

Number of pages: 28 Posted: 20 Feb 2025

Nan Ding, Karlijn E.P.E. Hermans, Thiemo J.A. van Nijnatten, Sanne M.E. Engelen, Jolien Tol, Loes Kooreman, Marie-Jeanne T.F.D. Vrancken Peeters, Sabine Siesling, Adri C. Voogd, Vivianne C.G. Tjan-Heijnen and Sandra M.E. Geurts

Maastricht University, Maastricht University, Maastricht University - Department of Radiology and Nuclear Medicine, Maastricht University - Department of Surgery, Jeroen Bosch Hospital, Maastricht University, Netherlands Cancer Institute Antoni van Leeuwenhoek, Netherlands Comprehensive Cancer Organisation, Maastricht University, Maastricht University and Maastricht University

Downloads 60

Nan Ding

Maastricht University

1

166

0

Scholarly Papers (1)

Overall Survival of Patients with De Novo HER2-Positive Metastatic Breast Cancer in the Netherlands from 2008 to 2017: A Population-Based Cohort Study

Overall Survival of Patients with De Novo HER2-Positive Metastatic Breast Cancer in the Netherlands from 2008 to 2017: A Population-Based Cohort Study

Abstract:

Overall Survival of Patients with de novo HER2-Positive Metastatic Breast Cancer in the Netherlands from 2008 to 2017: A Population-Based Cohort Study

Abstract: